624 related articles for article (PubMed ID: 9003111)
21. Low frequency of germline mutations in the RET proto-oncogene in patients with apparently sporadic medullary thyroid carcinoma.
Eng C; Mulligan LM; Smith DP; Healey CS; Frilling A; Raue F; Neumann HP; Ponder MA; Ponder BA
Clin Endocrinol (Oxf); 1995 Jul; 43(1):123-7. PubMed ID: 7641404
[TBL] [Abstract][Full Text] [Related]
22. Mutation analysis of the RET proto-oncogene in Dutch families with MEN 2A, MEN 2B and FMTC: two novel mutations and one de novo mutation for MEN 2A.
Landsvater RM; Jansen RP; Hofstra RM; Buys CH; Lips CJ; Ploos van Amstel HK
Hum Genet; 1996 Jan; 97(1):11-4. PubMed ID: 8557249
[TBL] [Abstract][Full Text] [Related]
23. Clinical characteristics and genetic screening of an extended family with MEN2A.
Algün E; Abaci N; Kösem M; Kotan C; Köseoğlu B; Boztepe H; Sekeroğlu R; Aslan H; Topal C; Ayakta H; Uygan I; Alagöl F; Erginel-Unaltuna N; Aksoy H
J Endocrinol Invest; 2002; 25(7):603-8. PubMed ID: 12150334
[TBL] [Abstract][Full Text] [Related]
24. Novel point mutation in exon 10 of the RET proto-oncogene in a family with medullary thyroid carcinoma.
Oriola J; Páramo C; Halperin I; García-Mayor RV; Rivera-Fillat F
Am J Med Genet; 1998 Jul; 78(3):271-3. PubMed ID: 9677065
[TBL] [Abstract][Full Text] [Related]
25. Adrenal and extra-adrenal pheochromocytomas in a family with germline RET V804L mutation.
Nilsson O; Tisell LE; Jansson S; Ahlman H; Gimm O; Eng C
JAMA; 1999 May; 281(17):1587-8. PubMed ID: 10235148
[No Abstract] [Full Text] [Related]
26. A large family with hereditary MTC: role of RET genetic analysis in differential diagnosis between MEN 2A and FMTC.
Chiefari E; Chiarella R; Crocetti U; Tardio B; Arturi F; Russo D; Trischitta V; Filetti S; Zingrillo M
Horm Metab Res; 2001 Jan; 33(1):52-6. PubMed ID: 11280716
[TBL] [Abstract][Full Text] [Related]
27. Presymptomatic DNA screening in families with multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma.
Frilling A; Dralle H; Eng C; Raue F; Broelsch CE
Surgery; 1995 Dec; 118(6):1099-103; discussion 1103-4. PubMed ID: 7491529
[TBL] [Abstract][Full Text] [Related]
28. Mutation of RET codon 768 is associated with the FMTC phenotype.
Boccia LM; Green JS; Joyce C; Eng C; Taylor SA; Mulligan LM
Clin Genet; 1997 Feb; 51(2):81-5. PubMed ID: 9111992
[TBL] [Abstract][Full Text] [Related]
29. Mutational analysis of the RET proto-oncogene in 71 Japanese patients with medullary thyroid carcinoma.
Shirahama S; Ogura K; Takami H; Ito K; Tohsen T; Miyauchi A; Nakamura Y
J Hum Genet; 1998; 43(2):101-6. PubMed ID: 9621513
[TBL] [Abstract][Full Text] [Related]
30. Biological properties of Ret with cysteine mutations correlate with multiple endocrine neoplasia type 2A, familial medullary thyroid carcinoma, and Hirschsprung's disease phenotype.
Ito S; Iwashita T; Asai N; Murakami H; Iwata Y; Sobue G; Takahashi M
Cancer Res; 1997 Jul; 57(14):2870-2. PubMed ID: 9230192
[TBL] [Abstract][Full Text] [Related]
31. Mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A (Sipple's syndrome).
Oishi S; Sato T; Takiguchi-Shirahama S; Nakamura Y
Endocr J; 1995 Aug; 42(4):527-36. PubMed ID: 8556060
[TBL] [Abstract][Full Text] [Related]
32. Multiple endocrine neoplasia type 2A with the identical somatic mutation in medullary thyroid carcinoma and pheochromocytoma without germline mutation at the corresponding site in the RET proto-oncogene.
Akama H; Noshiro T; Kimura N; Shimizu K; Watanabe T; Shibukawa S; Nakai S; Miura W; Ito S; Miura Y
Intern Med; 1999 Feb; 38(2):145-9. PubMed ID: 10225670
[TBL] [Abstract][Full Text] [Related]
33. Variable expressivity of familial medullary thyroid carcinoma (FMTC) due to a RET V804M (GTG-->ATG) mutation.
Feldman GL; Edmonds MW; Ainsworth PJ; Schuffenecker I; Lenoir GM; Saxe AW; Talpos GB; Roberson J; Petrucelli N; Jackson CE
Surgery; 2000 Jul; 128(1):93-8. PubMed ID: 10876191
[TBL] [Abstract][Full Text] [Related]
34. [Detection of RET-proto-oncogene mutations in the diagnosis of Type 2 endocrine neoplasia (MEN 2)].
Komminoth P; Muletta-Feurer S; Soltermann A; Gemsenjäger E; Bürgi H; Staub JJ; Schönle E; Fried M; Vetter W; Spinas GA; Heitz PU
Schweiz Med Wochenschr; 1996 Aug; 126(31-32):1329-38. PubMed ID: 8765374
[TBL] [Abstract][Full Text] [Related]
35. Screening of RET gene mutations in Chinese patients with medullary thyroid carcinoma and their relatives.
Wang J; Zhang B; Liu W; Zhang Y; Di X; Yang Y; Yan D
Fam Cancer; 2016 Jan; 15(1):99-104. PubMed ID: 26254625
[TBL] [Abstract][Full Text] [Related]
36. A RET double mutation in the germline of a kindred with FMTC.
Bartsch DK; Hasse C; Schug C; Barth P; Rothmund M; Höppner W
Exp Clin Endocrinol Diabetes; 2000; 108(2):128-32. PubMed ID: 10826520
[TBL] [Abstract][Full Text] [Related]
37. Mutations in the cysteine-rich region of the RET proto-oncogene in patients diagnosed as having sporadic medullary thyroid carcinoma.
Kimura T; Yoshimoto K; Yokogoshi Y; Saito S
Endocr J; 1995 Aug; 42(4):517-25. PubMed ID: 8556059
[TBL] [Abstract][Full Text] [Related]
38. Pheochromocytoma and medullary thyroid carcinoma: a new genotype-phenotype correlation of the RET protooncogene 891 germline mutation.
Jimenez C; Habra MA; Huang SC; El-Naggar A; Shapiro SE; Evans DB; Cote G; Gagel RF
J Clin Endocrinol Metab; 2004 Aug; 89(8):4142-5. PubMed ID: 15292360
[TBL] [Abstract][Full Text] [Related]
39. Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC.
Mulligan LM; Eng C; Healey CS; Clayton D; Kwok JB; Gardner E; Ponder MA; Frilling A; Jackson CE; Lehnert H
Nat Genet; 1994 Jan; 6(1):70-4. PubMed ID: 7907913
[TBL] [Abstract][Full Text] [Related]
40. [Study of RET protooncogene in multiple endocrine neoplasm 2A and in familial medullary thyroid carcinoma. Clinical pathological findings in asymptomatic carriers].
Belli S; Storani ME; Dourisboure RJ; Podestá EJ; Solano AR
Medicina (B Aires); 2003; 63(1):41-5. PubMed ID: 12673960
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]